StartUp / Biotech
Track biotech startups, life science innovation, health technology ventures and scientific commercialization trends with structured business briefings.
Big Ideas 2026: Multiomics
Summary
Multiomics integrates various biological layers to enhance understanding of health and disease. It encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics, which together provide a comprehensive view of biological systems. The cost of sequencing a human genome has dramatically decreased, leading to increased test volumes and biological data generation.
AI-driven drug development can significantly reduce costs and time to market, enhancing the economic viability of new therapies. Functional cures are emerging as a new model, priced substantially higher than traditional treatments due to their upfront value delivery. These therapies can durably eliminate disease activity after a limited course of treatment, representing a shift from chronic care models.
Global life expectancy has increased from 46 years in 1950 to 73 years in 2023, primarily due to advancements in disease prevention. Future increases in lifespan will depend on addressing the biological aging processes that affect health and resilience. Improved measurement techniques for biological aging are making it a more tractable target for scientific study and medical intervention.
Perspectives
short
Proponents of Multiomics and AI in Healthcare
- Define Multiomics as a comprehensive approach to understanding biology
- Highlight the reduction in genome sequencing costs and its implications for data generation
- Emphasize the potential of AI to reduce drug development costs and timelines
- Present functional cures as a transformative model in healthcare
- Discuss the significant economic potential of addressing biological aging
Skeptics of Projections in Multiomics and AI
- Question the assumptions behind projected cost reductions in genome sequencing
- Challenge the feasibility of AI universally reducing drug development costs
- Critique the linear relationship assumed between health interventions and lifespan extension
- Highlight potential regulatory hurdles and market dynamics affecting AI-enabled diagnostics
Neutral / Shared
- Acknowledge the rapid growth in biological data generation
- Recognize the importance of integrating multiple biological layers for comprehensive insights
- Note the advancements in measuring biological aging and their implications for healthcare
Metrics
cost
$100 USD
cost of sequencing a human genome today
Lower costs can lead to increased accessibility and testing.
the cost of sequence a whole human genome has fallen dramatically and can be as low as around $100 per genome
cost
$10 USD
projected cost of sequencing a human genome by 2030
A significant reduction could revolutionize genomic medicine.
by 2030, the cost could fall by another order of magnitude, reaching roughly $10 per genome
percentage
30%
projected share of AI-enabled diagnostics by 2030
Increased AI integration could enhance diagnostic accuracy.
the share of AI-enabled diagnostics and devices is projected to rise from roughly 10% today to about 30% by 2030
percentage
40%
reduction in time to market for AI-driven drug development
Faster drug development can lead to quicker patient access to new therapies.
AI-driven drug development has the potential to reduce time to market by roughly 40%
fold
10 fold
projected increase in biological data volume by 2030
A tenfold increase could enhance research and therapeutic development.
data volume will scale by 10 fold by 2030
percentage
10%
current share of AI-enabled diagnostics
Understanding the current landscape is crucial for assessing future growth.
the share of AI-enabled diagnostics and devices is projected to rise from roughly 10% today
percentage
more than double times
expected increase in next-gen molecular diagnostic tests by 2030
Increased testing can lead to earlier disease detection.
the total number of next-gen molecular diagnostic tests should more than double by the end of the decade
valuation
$3 billion USD
cumulative cash flow from an AI-developed drug
This indicates the potential financial impact of AI in drug development.
an AI-developed drug could generate roughly $3 billion in cumulative cash flow
Key entities
Timeline highlights
00:00–05:00
Multiomics integrates various biological layers to enhance understanding of health and disease. The cost of sequencing a human genome is projected to drop significantly, leading to increased test volumes and biological data generation.
- Multiomics integrates genomics, epigenomics, transcriptomics, proteomics, and metabolomics, enhancing our understanding of health and disease
- Sequencing a human genome has dropped from $2.7 billion to around $100, projected to reach $10 by 2030, increasing test volumes significantly
- Next-gen molecular diagnostic tests are expected to more than double by 2030, leading to a tenfold increase in biological data volume
- AI is transforming diagnostics, with FDA approvals for AI-enabled products rising from 10% to 30% by 2030
- AI-driven drug development could cut time to market by 40% and costs by fourfold, addressing pharmaceutical industry challenges
- The integration of multiomics and AI creates a cycle that improves therapeutics and diagnostics, enhancing disease treatment
05:00–10:00
AI-driven drug development can significantly reduce costs and time to market, enhancing the economic viability of new therapies. Functional cures are emerging as a new model, priced substantially higher than traditional treatments due to their upfront value delivery.
- AI-driven drug development can reduce time to market by 40% and costs by fourfold, enhancing economic viability
- Functional cures can be priced over $1 million per patient, significantly more than traditional therapies
- Cures can be up to 20 times more valuable than typical drugs, capturing revenue upfront
- Gene editing therapies for hereditary angioedema could prevent attacks, with lifetime costs reaching $20 million
- Gene editing is expanding into common conditions, with potential prices around $165,000 for cardiovascular therapies
- The market for gene editing targeting atherosclerotic cardiovascular disease could reach $2.8 trillion
10:00–15:00
Global life expectancy has increased from 46 years in 1950 to 73 years in 2023, primarily due to advancements in disease prevention. Future increases in lifespan will depend on addressing the biological aging processes that affect health and resilience.
- Global life expectancy rose from 46 years in 1950 to 73 years in 2023 due to disease prevention. Future lifespan extension depends on addressing biological aging processes